SkinBioTherapeutics (LON:SBTX - Get Free Report) posted its earnings results on Wednesday. The company reported GBX (0.46) (($0.01)) earnings per share for the quarter, Digital Look Earnings reports. SkinBioTherapeutics had a negative net margin of 237.95% and a negative return on equity of 115.86%.
SkinBioTherapeutics Price Performance
Shares of SBTX traded down GBX 0.23 ($0.00) during mid-day trading on Friday, reaching GBX 23.87 ($0.31). The company had a trading volume of 781,959 shares, compared to its average volume of 820,367. The company has a debt-to-equity ratio of 27.57, a current ratio of 0.93 and a quick ratio of 10.01. The company has a market capitalization of £54.53 million, a P/E ratio of -14.68 and a beta of 2.01. SkinBioTherapeutics has a twelve month low of GBX 8.32 ($0.11) and a twelve month high of GBX 26.45 ($0.34). The company's 50-day moving average is GBX 20.30 and its 200-day moving average is GBX 16.75.
About SkinBioTherapeutics
(
Get Free Report)
SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.
Featured Stories
Before you consider SkinBioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SkinBioTherapeutics wasn't on the list.
While SkinBioTherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
